Skip to main content

Search

Show all results for

Home

Person

Christian Hartinger

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (53)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Understanding the interactions of diruthenium anticancer agents with amino acids

Paul Joseph Dyson, Christian Hartinger, Alexey Nazarov, Muhammad Hanif

The dinuclear anticancer agents 1,n-bis{chlorido3-(oxo-kappa O)-2-methyl-4-(1H)-pyridinonato-kappa O4-ruthenium(II)}alkane (PyRu2n) exhibit high antiproliferative activity in human cancer cell. Reactivity studies with DNA and protein rev ...

SPRINGER2018

The development of RAPTA compounds for the treatment of tumors

Paul Joseph Dyson, Christian Hartinger, Benjamin Samuel Murray

Ruthenium(II)-arene RAPTA-type compounds have been extensively explored for their medicinal properties. Herein a comprehensive review of this class of compounds is provided. A discussion of the basic RAPTA structure is given together with the ways it has b ...

Elsevier Science Sa2016

Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action

Paul Joseph Dyson, Christian Hartinger

The clinical development of anticancer metallodrugs is often hindered by the elusive nature of their molecular targets. To identify the molecular targets of an antimetastatic ruthenium organometallic complex based on 1,3,5-triaza-7-phosphaadamantane (RAPTA ...

2015